albuterol sulfate (Amphastar) vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol sulfate (Amphastar)
Rights held by Amphastar Pharmaceuticals, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol sulfate (Amphastar) | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 |
| Trough FEV1, change | —Not reported | —Not posted · NCT00646620 |
| ACQ-5, change | —Not reported | —Not posted · NCT00646620 |
| OCS dose reduction | —Not reported | —Not posted · NCT00646620 |
Severe exacerbations, annualised rate
- albuterol sulfate (Amphastar)
- —Not reported
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
Trough FEV1, change
- albuterol sulfate (Amphastar)
- —Not reported
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
ACQ-5, change
- albuterol sulfate (Amphastar)
- —Not reported
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
OCS dose reduction
- albuterol sulfate (Amphastar)
- —Not reported
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
albuterol sulfate (Amphastar): no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol sulfate (Amphastar): 0 of 4 rows · Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|
| Dropout rate | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 50/100 mcg/daya upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair HFA)
+ 12 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol sulfate (Amphastar)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape